Loading...
XSHG600421
Market cap206mUSD
Dec 24, Last price  
7.70CNY
1D
-5.06%
1Q
19.38%
Name

Hubei Huarong Holding Co Ltd

Chart & Performance

D1W1MN
XSHG:600421 chart
P/E
—
P/S
12.33
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
2.99%
Rev. gr., 5y
161.29%
Revenues
122m
-2.45%
201,066,931196,893,290298,182,30818,142,93919,130,84318,936,64214,281,20710,756,2208,037,0408,368,91644,112,97127,852,36528,177,07928,767,3091,002,70423,267,767140,188,499130,352,941125,191,438122,123,443
Net income
-8m
27,279,66416,369,88615,314,9290054,812,08600119,748,05113,797,5362,169,673186,9243,210,023003,263,81715,407,97600-8,279,504
CFO
6m
0016,033,0460070,242,35166,210069,315,04801,966,64500006,097,9250006,016,092
Earnings
May 23, 2025

Profile

Hubei Huarong Holding Co.,Ltd. produces and distributes pharmaceutical products in China. The company's principal pharmaceutical products include Gucining Capsules and Huoxue Tongmai Capsules. It also develops biological products, pharmaceuticals, environment-protection, and agricultural products, as well as related technologies. The company was formerly known as Hubei Yangfan Holding Co., Ltd. and changed its name to Hubei Huarong Holding Co.,Ltd. in November 2020. Hubei Huarong Holding Co.,Ltd. was founded in 1997 and is headquartered in Wuhan, China.
URL
spring.com.cn
IPO date
Jun 07, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
122,123
-2.45%
125,191
-3.96%
130,353
-7.02%
Cost of revenue
113,926
123,538
128,649
Unusual Expense (Income)
NOPBT
8,198
1,653
1,704
NOPBT Margin
6.71%
1.32%
1.31%
Operating Taxes
1,069
Tax Rate
13.03%
NOPAT
7,129
1,653
1,704
Net income
(8,280)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
53,982
16,272
16,613
Long-term debt
5,735
7,434
14,483
Deferred revenue
234
343
1
Other long-term liabilities
800
800
800
Net debt
56,037
6,337
(4,707)
Cash flow
Cash from operating activities
6,016
CAPEX
Cash from investing activities
(16,967)
Cash from financing activities
10,914
14,239
FCF
(26,898)
133
(13,650)
Balance
Cash
3,680
3,704
16,310
Long term investments
1
13,664
19,494
Excess cash
11,109
29,287
Stockholders' equity
(156,183)
282,379
281,843
Invested Capital
253,434
51,418
42,782
ROIC
4.68%
3.51%
3.78%
ROCE
8.37%
2.64%
2.36%
EV
Common stock shares outstanding
206,988
195,600
195,600
Price
11.13
3.15%
10.79
12.63%
9.58
-0.73%
Market cap
2,303,772
9.16%
2,110,524
12.63%
1,873,848
-0.73%
EV
2,386,377
2,142,214
1,893,964
EBITDA
13,172
7,128
7,079
EV/EBITDA
181.17
300.52
267.54
Interest
2,628
1,030
1,582
Interest/NOPBT
32.06%
62.31%
92.84%